ENDRA Life Sciences Inc(NDRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NDRA ENDRA Life Sciences Inc

Post-Mkt 12-11 18:51:38 EST

5.92

+0.06

+1.02%

盘后5.81

-0.11-1.86%

16:59 EST

High5.94	Low5.52	Vol57.68K
Open5.64	D1 Closing5.86	Amplitude7.17%
Mkt Cap6.91M	Tradable Cap6.91M	Total Shares1.17M
T/O334.27K	T/O Rate4.95%	Tradable Shares1.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NDRA","market":"US","secType":"STK","nameCN":"ENDRA Life Sciences Inc","latestPrice":5.92,"timestamp":1765486800000,"preClose":5.86,"halted":0,"volume":57683,"hourTrading":{"tag":"盘后","latestPrice":5.81,"preClose":5.92,"latestTime":"16:59 EST","volume":1632,"amount":9682.63968,"timestamp":1765490356713},"delay":0,"floatShares":1166400,"shares":1166441,"eps":-17.008213,"marketStatus":"Post-Mkt","change":0.06,"latestTime":"12-11 18:51:38 EST","open":5.64,"high":5.94,"low":5.52,"amount":334274.6924168,"amplitude":0.071672,"askPrice":5.98,"askSize":200,"bidPrice":5.75,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-17.008213,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765501200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":5.86,"preHourTrading":{"tag":"盘前","latestPrice":5.64,"preClose":5.86,"latestTime":"09:25 EST","volume":2278,"amount":13045.805304,"timestamp":1765463145260},"postHourTrading":{"tag":"盘后","latestPrice":5.81,"preClose":5.92,"latestTime":"16:59 EST","volume":1632,"amount":9682.63968,"timestamp":1765490356713},"volumeRatio":0.222692},"requestUrl":"/m/hq/s/NDRA/wiki","defaultTab":"wiki","newsList":[{"id":"2589311923","title":"ENDRA Life Sciences Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2589311923","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589311923?lang=en_us&edition=fundamental","pubTime":"2025-12-08 18:25","pubTimestamp":1765189500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NDRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 05:25 ET (10:25 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDRA","BK4082"],"gpt_icon":0},{"id":"2588884239","title":"ENDRA Life Sciences Reports TAEUS Device Matches MRI Accuracy in Liver Disease Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2588884239","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588884239?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:01","pubTimestamp":1764853263,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences Inc. has announced new results from a recently completed feasibility study of its TAEUS Liver device, designed for the early detection and monitoring of steatotic liver disease . The study, which included 40 subjects with a BMI range of 21 to 47, demonstrated that the TAEUS thermo-acoustic fat fraction  measurement closely matches the performance of MRI-PDFF, the current gold standard, at key liver fat fraction  thresholds of 12-17% and 20-22%. These thresholds are significant for clinical therapy decisions and clinical trial enrollment. The device achieved an average positive predictive value  of 100% and accuracy of 95% in the 12-17% LFF range, and a PPV of 90% and accuracy of 94% in the 20-22% range. ENDRA is conducting a second feasibility study in London, Ontario, Canada, expected to be completed in the coming months, and plans to engage with the FDA in 2026 regarding a pivotal study to support a De Novo submission.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL9WpQd9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDRA","BK4082"],"gpt_icon":0},{"id":"2588840458","title":"ENDRA Life Sciences Inc - Second Feasibility Study for Taeus Liver Device Begun in London, Ontario","url":"https://stock-news.laohu8.com/highlight/detail?id=2588840458","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588840458?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUABXN0BH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NDRA"],"gpt_icon":0},{"id":"2588088492","title":"ENDRA’s Taeus® Liver Matches Mri-Pdff Performance at Key Clinical Thresholds, Positioning Device for Masld/Mash Trial Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2588088492","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588088492?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUABXN0BH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NDRA"],"gpt_icon":0},{"id":"2587737725","title":"ENDRA Life Sciences CTO Resigns as CFO Compensation Terms Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2587737725","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587737725?lang=en_us&edition=fundamental","pubTime":"2025-11-29 05:23","pubTimestamp":1764365021,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences Inc. announced that Michael Thornton has resigned as Chief Technology Officer and will continue to provide commercialization services to the company as a consultant. Additionally, Richard Jacroux, the company's Chief Financial Officer, will continue to serve as Principal Financial Officer and Principal Accounting Officer under a new advisory services agreement with Impact Solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ENDRA Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 28, 2025, and is solely responsible for the information cont","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL3tqSZq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1989772840.SGD","NDRA","BK4566","BK4534","PFG","BK4588","BK4082","BK4162","LU1989772923.USD"],"gpt_icon":0},{"id":"2584131725","title":"ENDRA Life Sciences Reports Positive Feasibility Study Results for TAEUS Liver Fat Quantification Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2584131725","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584131725?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:01","pubTimestamp":1763643711,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences Inc. has announced encouraging preliminary results from a single-site clinical feasibility study evaluating its improved TAEUS Liver device for quantifying liver fat fraction, a key biomarker in steatotic liver disease , including MASLD and MASH. According to the company, the TAEUS Liver device demonstrated strong agreement with the current imaging gold standard, MRI-PDFF, across the full spectrum of steatotic liver disease and patient BMI. These results aim to validate the improved performance of the device and inform the design and statistical plan for a pivotal study in consultation with the U.S. Food and Drug Administration . A second feasibility study is currently underway in London, Ontario, Canada, with completion expected in the coming months. Results from these studies will be discussed with the FDA in pre-submission meetings prior to initiating the pivotal study and are also expected to be submitted for publication in a peer-reviewed medical journal.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL2k708r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDRA","BK4082"],"gpt_icon":0},{"id":"2584263916","title":"ENDRA Life Sciences Q3 EPS $(2.10) Misses $(1.95) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2584263916","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584263916?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:20","pubTimestamp":1763385624,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(2.10) per share which missed the analyst consensus estimate of $(1.95) by 7.69 percent. This is a 77.99 percent increase over losses of $(9.54) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48896449/endra-life-sciences-q3-eps-2-10-misses-1-95-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".IXIC","SQQQ","TSYW.SI","QID","BK4082","PSQ","USAW.SI","USJW.SI","NQmain","NVIW.SI","TQQQ","MNQmain","NDRA","QLD"],"gpt_icon":0},{"id":"2584625995","title":"ENDRA Life Sciences reports third quarter cash burn down 30% to $1.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584625995","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584625995?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:06","pubTimestamp":1763384798,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences Inc. reported a 30% decrease in cash burn from operations for the third quarter of 2025, totaling $1.2 million compared to $1.7 million in the same period of 2024. Total operating expenses for the quarter were $1.4 million, down from $1.5 million a year ago. As of September 30, 2025, the company had $0.8 million in cash and cash equivalents. After the quarter ended, ENDRA raised $4.9 million in gross proceeds through a private placement. The company also regained Nasdaq compliance following the financing. In addition, ENDRA completed a single site clinical feasibility study of its redesigned TAEUS Liver device and launched a strategic initiative to enhance balance sheet flexibility through a reward-generating program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL57LG5b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NDRA"],"gpt_icon":0},{"id":"2584625515","title":"Press Release: ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2584625515","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584625515?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:00","pubTimestamp":1763384400,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences Inc.  , a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease  and metabolic dysfunction associated steatohepatitis , today provided a business update and reported financial results for the three and nine months ended September 30, 2025.--  Completed private placement of up to $14.4 million. On October 23,financing led by institutional investors. The PIPE generated gross. proceeds of approximately $4.9 million before placement agent fees and. year, ENDRA launched a strategic initiative designed to strengthen the. ENDRA deployed a portion of its capital into an institutional grade. providing supplemental financial resources to support ENDRA's operational. ENDRA confirms that it will soon release key results from its recently. \"We're at a transformative inflection point,\" said Alexander Tokman, ENDRA's Chief Executive Officer. \"We have advanced on two critical fronts: financial sustainabili","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","PIPE","BK4022","R","NDRA","BK4082","NQmain"],"gpt_icon":0},{"id":"2583868476","title":"ENDRA Life Sciences Raises $4.9 Million in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2583868476","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583868476?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:33","pubTimestamp":1763155990,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences Inc. has completed a private placement offering, issuing a total of 744,340 shares of common stock or prefunded warrants in lieu thereof, alongside warrants to purchase up to 1,488,680 shares of common stock. The warrants carry an exercise price of $6.32 per share, or $6.81 for warrants purchased by a board member. The offering generated approximately $4.9 million in gross proceeds. This transaction was part of the company's strategy to regain compliance with the Nasdaq minimum stockholders' equity requirement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ENDRA Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL6DkBSV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDRA","BK4082"],"gpt_icon":0},{"id":"2583551504","title":"ENDRA Life Sciences Commences Staking of its HYPE Digital Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2583551504","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583551504?lang=en_us&edition=fundamental","pubTime":"2025-11-14 03:20","pubTimestamp":1763061656,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences  said Thursday that it has commenced the staking its holdings of HYPE, the native token of the Hyperliquid ecosystem.The staking initiative is expected to maximize the utility and return of the company's HYPE while, contributing towards the security and decentralization of the underlying blockchain network, ENDRA said.The company said it is converting static treasury assets into a rewards engine to assist medical innovation.Shares of the company were up 4% in recent Thursday trading.Price: 6.51, Change: +0.25, Percent Change: +3.99","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NDRA","BK4082"],"gpt_icon":0},{"id":"2583560007","title":"ENDRA Life Sciences Outlines Ongoing Digital Asset Strategy with Plans to Stake HYPE Tokens, Enhance Balance Sheet Diversification, and Explore Further DeFi Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2583560007","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583560007?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:01","pubTimestamp":1763038899,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences Outlines Ongoing Digital Asset Strategy with Plans to Stake HYPE Tokens, Enhance Balance Sheet Diversification, and Explore Further DeFi Opportunities. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ENDRA Life Sciences Inc. published the original content used to generate this news brief via Business Wire  on November 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL4wGq61:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NDRA"],"gpt_icon":0},{"id":"2579611968","title":"BRIEF-ENDRA Life Sciences Inc Enters ATM Agreement With Lucid For Up To $1.75 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2579611968","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579611968?lang=en_us&edition=fundamental","pubTime":"2025-10-30 18:14","pubTimestamp":1761819251,"startTime":"0","endTime":"0","summary":"BRIEF-ENDRA Life Sciences Inc Enters ATM Agreement With Lucid For Up To $1.75 Million - SEC FilingOct 30  - ENDRA Life Sciences Inc NDRA.O:ENDRA LIFE SCIENCES INC - ON OCT 29, ENTERS ATM AGREEMENT WITH LUCID FOR UP TO $1.75 MILLION - SEC FILINGENDRA LIFE SCIENCES INC - TO PAY LUCID UP TO 3.0% COMMISSION - SEC FILINGSource text: [ID:n0001213900-25-103707]Further company coverage: NDRA.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nFWN3WB13K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NDRA"],"gpt_icon":0},{"id":"2579116087","title":"ENDRA Life Sciences Inc -on Oct 29, Enters Atm Agreement With Lucid for up to $1.75 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2579116087","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579116087?lang=en_us&edition=fundamental","pubTime":"2025-10-30 18:11","pubTimestamp":1761819096,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nFWN3WB13K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NDRA"],"gpt_icon":0},{"id":"2577930923","title":"ENDRA Life Sciences Raises $4.9 Million in Private Placement and Launches Crypto Treasury Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2577930923","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577930923?lang=en_us&edition=fundamental","pubTime":"2025-10-23 20:00","pubTimestamp":1761220852,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences Inc. has announced the successful closing of a private investment in public equity  financing, raising approximately $4.9 million in gross proceeds from institutional and cryptocurrency investors. The financing includes the potential for an additional $9.5 million in gross proceeds from future warrant exercises. Alongside the financing, ENDRA has launched a digital asset treasury strategy, initially deploying $3 million into HYPE tokens, a leading asset in the decentralized perpetual futures ecosystem. The company aims to enhance long-term shareholder value through active digital asset management and yield-generation strategies. Lucid Capital Markets served as the sole placement agent for the offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL6y1M8v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NDRA"],"gpt_icon":0},{"id":"2577309962","title":"ENDRA Life Sciences Closes up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy With $3 Million in Initial Hype Token Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2577309962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577309962?lang=en_us&edition=fundamental","pubTime":"2025-10-23 20:00","pubTimestamp":1761220802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUA9L03KT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NDRA"],"gpt_icon":0},{"id":"2576061862","title":"ENDRA Life Sciences Inc. Announces Date for Upcoming Annual Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2576061862","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576061862?lang=en_us&edition=fundamental","pubTime":"2025-10-18 04:27","pubTimestamp":1760732820,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences Inc. will hold its 2025 Annual Meeting of Stockholders on December 9, 2025. During the meeting, stockholders will vote to elect four director nominees named in the proxy statement to serve one-year terms expiring at the 2026 annual meeting of stockholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ENDRA Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL4bXHm4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NDRA"],"gpt_icon":0},{"id":"2575510147","title":"ENDRA Life Sciences Issues Correction to October 15, 2025, SEC Filing to Address Technical Submission Error","url":"https://stock-news.laohu8.com/highlight/detail?id=2575510147","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575510147?lang=en_us&edition=fundamental","pubTime":"2025-10-16 05:01","pubTimestamp":1760562106,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences Inc. issued an amendment to its previously filed Form 8-K, correcting a technical error involving the coding of certain items in the EDGAR submission. No changes were made to the text or exhibits of the original filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ENDRA Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL1zNhQf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDRA","BK4082"],"gpt_icon":0},{"id":"2575178030","title":"ENDRA Life Sciences Announces $14.4 Million Private Placement to Launch Digital Asset Treasury Strategy Managed by Arca","url":"https://stock-news.laohu8.com/highlight/detail?id=2575178030","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575178030?lang=en_us&edition=fundamental","pubTime":"2025-10-15 21:09","pubTimestamp":1760533793,"startTime":"0","endTime":"0","summary":"ENDRA Life Sciences Inc. has announced a private placement of up to $14.4 million to launch a digital asset treasury  strategy managed by Arca Investment Management. The company has already secured $4.9 million in commitments from institutional and cryptocurrency investors. The majority of the net proceeds will be used to establish ENDRA's DAT operations and accumulate cryptocurrency, focusing on decentralized exchanges and protocols, particularly those related to perpetual futures. The remaining funds will support the completion of a pilot validation imaging study for liver disease technologies. Jeff Dorman is expected to join ENDRA's Digital Asset Advisory Board to help guide the new strategy. Lucid Capital Markets acted as the sole placement agent for the offering.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL4JGJlV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1988902786.USD","LU0496365809.HKD","LU1732800096.USD","IE00B19Z3581.USD","IE00B19Z9Z06.USD","LU1119994496.HKD","LU0203347892.USD","BK4588","BK4533","LU1989771016.USD","LU1066053197.SGD","IE00B4JS1V06.HKD","SG9999018857.SGD","LU0965509010.AUD","SG9999014880.SGD","BK4566","LU0557290698.USD","LU0689472784.USD","IE00B1BXHZ80.USD","LU0795875086.SGD","SG9999014906.USD","LU2125154778.USD","LU0048584097.USD","LU1914381329.SGD","IE0004445239.USD","IE00BJT1NW94.SGD","LU0545039389.USD","LU2324357040.USD","SG9999001176.SGD","NDRA","IE00BFSS8Q28.SGD","LU2468319806.SGD","LU0128525689.USD","LU2362540622.SGD","LU0149725797.USD","IE0002270589.USD","LU0943347566.SGD","SG9999018865.SGD","LU1323610961.USD","LU0787776722.HKD","LU1983299246.USD","LU1670628061.USD","LU2552382215.SGD","IE00BSNM7G36.USD","LU2271345857.HKD","IE00B19Z9505.USD","BK4585","LU0320765059.SGD","LU1791710582.SGD"],"gpt_icon":1},{"id":"2575927352","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2575927352","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575927352?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:45","pubTimestamp":1760442342,"startTime":"0","endTime":"0","summary":"Powell Max  shares were 21% lower pre-bell Tuesday, reversing from Monday's increase.Namib Minerals  stock was down 20%, shaving gains from the previous session.Orion  shares were 19% lower, a day after the company lowered its full-year 2025 adjusted EBITDA guidance.ENDRA Life Sciences  stock was down 17%, following a 25% increase in the previous session.PS International  shares were 14% lower, paring Monday's rally.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4017","BK4090","NAMM","BK4112","OEC.AU","PMAX","OEC","NDRA","PSIG","BK4082","BK7115","BK4131"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.endrainc.com","stockEarnings":[{"period":"1week","weight":-0.0163},{"period":"1month","weight":0.0616},{"period":"3month","weight":0.2711},{"period":"6month","weight":0.6986},{"period":"1year","weight":0.1815},{"period":"ytd","weight":-0.0639}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.079347},{"month":2,"riseRate":0.25,"avgChangeRate":-0.077699},{"month":3,"riseRate":0.25,"avgChangeRate":-0.184803},{"month":4,"riseRate":0.25,"avgChangeRate":-0.100698},{"month":5,"riseRate":0.125,"avgChangeRate":-0.13671},{"month":6,"riseRate":0.75,"avgChangeRate":0.032519},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.005394},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.12196},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.06489},{"month":10,"riseRate":0.222222,"avgChangeRate":0.02267},{"month":11,"riseRate":0.444444,"avgChangeRate":-0.075145},{"month":12,"riseRate":0.555556,"avgChangeRate":0.201668}],"exchange":"NASDAQ","name":"ENDRA Life Sciences Inc","nameEN":"ENDRA Life Sciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ENDRA Life Sciences Inc(NDRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ENDRA Life Sciences Inc(NDRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ENDRA Life Sciences Inc,NDRA,ENDRA Life Sciences Inc股票,ENDRA Life Sciences Inc股票老虎,ENDRA Life Sciences Inc股票老虎国际,ENDRA Life Sciences Inc行情,ENDRA Life Sciences Inc股票行情,ENDRA Life Sciences Inc股价,ENDRA Life Sciences Inc股市,ENDRA Life Sciences Inc股票价格,ENDRA Life Sciences Inc股票交易,ENDRA Life Sciences Inc股票购买,ENDRA Life Sciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ENDRA Life Sciences Inc(NDRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ENDRA Life Sciences Inc(NDRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}